Sepsis Diagnostics

Sepsis Diagnostics Market Outlook

The global sepsis diagnostics market is projected to reach approximately USD 5.3 billion by 2035, growing at a CAGR of about 9.6% from 2025 to 2035. This growth is primarily driven by the increasing incidence of sepsis worldwide, rising awareness regarding early diagnosis, and advancements in diagnostic technologies. Additionally, the growing geriatric population, which is more susceptible to infections and sepsis, alongside the rising prevalence of chronic diseases, significantly contributes to the market expansion. With the ongoing efforts to reduce sepsis-related morbidity and mortality through enhanced diagnostic methods, healthcare providers are increasingly investing in advanced sepsis diagnostics solutions, leading to a favorable market environment.

Growth Factor of the Market

The sepsis diagnostics market is witnessing substantial growth due to various factors that contribute to increased demand for effective diagnostic solutions. One of the significant growth factors is the rising incidence of sepsis, which has become a leading cause of morbidity and mortality in hospitals globally. In addition, awareness campaigns and initiatives taken by healthcare organizations to educate both medical professionals and the public about the importance of early detection are further fueling market growth. Technological advancements, including point-of-care testing and the development of rapid tests, enhance the speed and accuracy of sepsis diagnosis, making it easier for clinicians to initiate timely treatment. Furthermore, the increased investment in healthcare infrastructure and the adoption of advanced healthcare informatics systems also play a crucial role in driving the growth of the sepsis diagnostics market.

Key Highlights of the Market

• Growing global awareness regarding the importance of early sepsis diagnosis.
• Technological advancements leading to rapid and accurate diagnostic methods.
• Increase in government initiatives promoting better healthcare practices.
• Rising prevalence of hospital-acquired infections contributing to market growth.
• Expansion of healthcare facilities and infrastructure in developing regions.

By Product Type

Blood Culture Systems:

Blood culture systems represent a critical component of the sepsis diagnostics market, as they are essential for detecting the presence of pathogens in the bloodstream. These systems are designed to monitor blood samples for microbial growth, which is key to diagnosing bloodstream infections. The advancement in automated blood culture systems has significantly improved the efficiency and accuracy of testing, enabling faster results and reducing the time to diagnosis. Factors such as the increasing incidence of bacteremia and the need for rapid diagnostic solutions contribute to the growing demand for blood culture systems in hospitals and diagnostic laboratories. With technological innovations such as enhanced culture media and automated monitoring systems, blood culture systems are expected to maintain a significant share of the market.

Immunoassays:

Immunoassays are increasingly being utilized in the sepsis diagnostics market for their ability to quantitatively measure biomarkers associated with sepsis. These tests utilize antibodies to detect specific proteins, providing clinicians with valuable information regarding the presence and severity of an infection. The growing adoption of immunoassays is driven by their high sensitivity and specificity, which allow for accurate and timely diagnosis of sepsis. Furthermore, the integration of advanced technologies such as ELISA (Enzyme-Linked Immunosorbent Assay) and multiplex immunoassays enhances the capabilities of these tests, enabling simultaneous detection of multiple biomarkers. As sepsis diagnosis increasingly relies on biomarker identification, the immunoassay segment is expected to witness robust growth in the coming years.

Molecular Diagnostics:

Molecular diagnostics is one of the fastest-growing segments in the sepsis diagnostics market due to its ability to identify pathogens at a genetic level. Techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) offer rapid and precise detection of the organisms responsible for sepsis. The demand for molecular diagnostics is bolstered by the need for timely, accurate results and the ability to detect antibiotic resistance markers, which are crucial for effective treatment strategies. As healthcare providers increasingly adopt molecular diagnostic techniques to complement traditional methods, this segment is anticipated to experience significant growth, particularly in emergency care settings where rapid decision-making is critical.

Flow Cytometry:

Flow cytometry is a powerful tool utilized in the sepsis diagnostics market for cell analysis and characterization. It allows for the rapid analysis of multiple physical and chemical characteristics of cells as they flow in a fluid stream through a laser beam. This technique is particularly useful for identifying immune cell populations and their response to infection, providing insights into the patient’s immune status. The increasing utilization of flow cytometry in clinical laboratories for sepsis diagnosis is driven by its ability to deliver real-time data and its application in research settings to better understand the pathophysiology of sepsis. As the focus on personalized medicine grows, the role of flow cytometry in sepsis diagnostics is expected to expand significantly.

Microbiology:

The microbiology segment plays a pivotal role in the sepsis diagnostics market, focusing on the culture and identification of pathogens from clinical specimens. Traditional microbiological methods, alongside modern automated systems, allow for the isolation and identification of bacteria and fungi, which are essential for diagnosing sepsis. The growing emphasis on laboratory accreditation and quality assurance in microbiology laboratories enhances the reliability of diagnostic results. Additionally, the integration of molecular techniques with conventional microbiological methods is facilitating faster turnaround times, thereby improving patient outcomes. As the demand for accurate pathogen identification continues to rise, the microbiology segment is expected to maintain a significant position in the sepsis diagnostics market.

Others:

The 'Others' category encompasses various diagnostic methods and tools that do not fall neatly into the previously mentioned segments. This may include point-of-care devices, mass spectrometry techniques, and other emerging technologies that contribute to sepsis diagnosis. The growth in this segment is driven by the need for innovative solutions that provide rapid, efficient, and accurate diagnostics in diverse clinical settings. As healthcare systems increasingly prioritize quick diagnosis and treatment initiation, the market for alternative diagnostic methods is likely to expand. The integration of novel technologies and the ongoing research into new diagnostic approaches will further support the growth of this segment in the sepsis diagnostics market.

By Application

Hospitals:

Hospitals account for the largest share of the sepsis diagnostics market due to the high incidence of sepsis cases presenting in emergency departments. With the increasing focus on patient safety and quality of care, hospitals are investing in advanced diagnostic technologies to facilitate early detection and treatment of sepsis. The implementation of sepsis protocols and the establishment of rapid response teams in hospitals have led to improved outcomes and reduced mortality rates. As the demand for effective sepsis management continues to rise, hospitals are likely to remain a key application segment, driving the demand for diagnostic solutions that enable timely intervention.

Diagnostic Laboratories:

Diagnostic laboratories play a critical role in the sepsis diagnostics market by providing essential testing services to healthcare providers. These laboratories are equipped with advanced technologies that allow for the efficient processing of samples and the accurate identification of pathogens. The rising demand for laboratory testing, fueled by an increasing number of sepsis cases and the continuous evolution of testing methodologies, is expected to propel the growth of this segment. Moreover, the trend towards outsourcing laboratory services by hospitals and clinics further enhances the significance of diagnostic laboratories in the sepsis diagnostics ecosystem, fostering a collaborative approach to patient care.

Research Laboratories:

Research laboratories significantly contribute to the sepsis diagnostics market by developing innovative diagnostic methods and enhancing our understanding of the underlying mechanisms of sepsis. These facilities engage in extensive research and development activities, focusing on identifying novel biomarkers, improving existing diagnostic tools, and conducting clinical trials to validate new technologies. Collaboration between research institutions and healthcare organizations fosters the development of cutting-edge diagnostic solutions, which ultimately translate into better patient outcomes. As the push for innovation in sepsis diagnosis continues, research laboratories are expected to play an increasingly vital role in shaping the future of the market.

Others:

The 'Others' category within the application segment encompasses various settings where sepsis diagnostics are utilized, such as outpatient clinics, home healthcare services, and emergency medical services. These environments increasingly recognize the importance of timely sepsis diagnosis and are adopting diagnostic tools that cater to their specific needs. The growing trend of decentralizing healthcare services and the increasing use of portable diagnostic devices are driving the growth of this segment. As awareness regarding sepsis rises and healthcare systems evolve to provide more accessible care, the 'Others' application segment is expected to expand significantly.

By Technology

Conventional Diagnostics:

Conventional diagnostics refer to traditional methods employed for diagnosing sepsis, including blood cultures, serological tests, and microscopy. Despite the emergence of advanced technologies, conventional diagnostics continue to play a crucial role due to their established reliability and effectiveness in various clinical settings. These methods, although slower in comparison to newer technologies, provide a foundational approach to identifying pathogens and determining the appropriate course of treatment. The integration of conventional diagnostic techniques with newer methodologies is expected to enhance overall diagnostic accuracy and patient management as healthcare professionals seek to balance speed and reliability.

Automated Diagnostics:

Automated diagnostics represent a paradigm shift in the sepsis diagnostics market, offering rapid and efficient testing solutions to healthcare providers. These systems utilize advanced technologies such as robotics, artificial intelligence, and high-throughput screening to streamline the diagnostic process, reducing turnaround times and minimizing the risk of human error. The growing adoption of automated diagnostics is driven by the increasing pressure on laboratories to manage high volumes of tests while maintaining accuracy and quality. As healthcare facilities continue to embrace automation to improve workflow and enhance patient care, the automated diagnostics segment is poised for substantial growth in the coming years.

By Test Type

Blood Culture Test:

The blood culture test remains the gold standard in sepsis diagnosis, allowing for the detection of pathogens present in the bloodstream. This test involves inoculating blood samples into culture media to encourage the growth of microorganisms, which can then be identified through various techniques. The growing prevalence of bloodstream infections and the need for accurate identification of pathogens drive the demand for blood culture tests. Advances in culture techniques and automated blood culture systems have significantly improved the efficiency and turnaround time for these tests, ensuring timely identification of sepsis and the initiation of appropriate treatment.

Biomarker Test:

Biomarker tests play a vital role in the early detection of sepsis by measuring specific proteins or molecules associated with the inflammatory response. These tests, including procalcitonin (PCT) and C-reactive protein (CRP), provide valuable insights into the presence and severity of sepsis. The increasing focus on personalized medicine and targeted therapies has led to a growing emphasis on biomarker testing for sepsis diagnosis. As healthcare providers seek to make informed clinical decisions based on objective data, the demand for biomarker tests is expected to rise, facilitating better patient management and outcomes in sepsis cases.

Complete Blood Count:

Complete blood count (CBC) is a widely used diagnostic test that evaluates several parameters related to blood components, including red blood cells, white blood cells, and platelets. In the context of sepsis, CBC plays a crucial role in providing information about the patient's immune response and overall health status. The results of a CBC can help healthcare providers identify signs of infection, inflammation, and potential organ dysfunction. As sepsis diagnosis increasingly relies on a combination of laboratory tests, the CBC will continue to be an essential component of the diagnostic process, providing critical insights into the patient's condition.

Urine Analysis:

Urine analysis is an important diagnostic tool in the sepsis diagnostics market, particularly for detecting urinary tract infections (UTIs), which can lead to sepsis. This test examines the physical, chemical, and microscopic properties of urine to identify abnormalities that may indicate infection. The rising incidence of UTIs, especially among vulnerable populations such as the elderly and immunocompromised individuals, has led to increased demand for urine analysis in sepsis diagnosis. As healthcare providers adopt more comprehensive approaches to sepsis management, urine analysis is expected to remain a valuable testing modality in the diagnostic arsenal.

Other Tests:

The 'Other Tests' category encompasses various diagnostic methods employed in sepsis diagnosis that do not fall under the previous classifications. This may include advanced imaging techniques, such as CT scans and MRIs, and rapid antigen detection tests. The evolution of diagnostic methodologies and the emergence of novel testing technologies contribute to the growth of this segment. As healthcare professionals seek to employ a holistic approach to sepsis diagnosis, the integration of diverse testing modalities will enhance the accuracy and timeliness of clinical decision-making, ultimately improving patient outcomes.

By Region

The sepsis diagnostics market exhibits notable variations across different regions, influenced by factors such as healthcare infrastructure, prevalence of sepsis, and technological adoption. North America holds a significant share of the market, driven by advanced healthcare facilities, high awareness levels, and substantial investment in research and development. The region is anticipated to witness a CAGR of 10.2% during the forecast period, reflecting its leading position in innovative diagnostic solutions. Europe also presents a robust market for sepsis diagnostics, with increased emphasis on improving healthcare quality and patient safety. Countries such as Germany, the UK, and France are at the forefront of adopting advanced diagnostics technologies to combat sepsis effectively.

In the Asia Pacific region, the sepsis diagnostics market is experiencing rapid growth due to factors such as rising population, increasing healthcare expenditure, and heightened awareness of infectious diseases. Countries like India and China are witnessing a surge in the demand for diagnostic solutions, contributing to a robust CAGR of around 9.0%. Latin America and the Middle East & Africa exhibit steady growth in the sepsis diagnostics market, driven by the increasing prevalence of infectious diseases and the expansion of healthcare facilities. As investments in healthcare infrastructure continue in these regions, the market for sepsis diagnostics is expected to flourish, addressing the growing burden of sepsis effectively.

Opportunities

The sepsis diagnostics market presents a plethora of opportunities for innovation and growth, particularly as the healthcare landscape continues to evolve. One of the most significant opportunities lies in the development of rapid, point-of-care diagnostic tests. These tests can provide immediate results at the patient's bedside, enabling healthcare providers to initiate timely treatment, which is crucial for sepsis management. The demand for such rapid diagnostics is increasing in both hospital and outpatient settings, particularly in regions with limited laboratory access. Additionally, advancements in technology, such as the incorporation of artificial intelligence and machine learning, hold the potential to revolutionize sepsis diagnostics by enhancing data interpretation and predictive analytics. As healthcare systems strive for improved patient outcomes, the integration of innovative technologies in sepsis diagnostics will present lucrative opportunities for market players.

Another opportunity within the sepsis diagnostics market is the growing focus on personalized medicine. As healthcare shifts towards tailored approaches to treatment, the demand for diagnostic solutions that provide insights into individual patient profiles and susceptibility to sepsis is increasing. This trend is driving research into identifying novel biomarkers that can predict sepsis risk and inform clinical decision-making. Companies that invest in research and development to create personalized diagnostic solutions will be well-positioned to capitalize on this trend. Additionally, strategic collaborations between diagnostic companies and healthcare institutions can enhance innovation and accelerate the development of new diagnostic tools, further driving market growth and improving patient outcomes.

Threats

Despite the promising outlook for the sepsis diagnostics market, several threats could pose challenges to its growth trajectory. One of the primary threats is the high cost associated with advanced diagnostic technologies, which may limit accessibility in underserved regions and healthcare settings. The financial constraints faced by healthcare providers in low- and middle-income countries can hinder the adoption of innovative diagnostic solutions, potentially leading to delayed diagnosis and treatment of sepsis. Furthermore, the ongoing global economic fluctuations may impact healthcare budgets, leading to reduced spending on advanced diagnostics. As such, addressing cost barriers and ensuring equitable access to sepsis diagnostics will be crucial for maximizing the market’s potential.

Another significant threat to the sepsis diagnostics market is the rapid emergence of antibiotic-resistant pathogens. The increasing prevalence of multidrug-resistant bacteria poses a considerable challenge to effective treatment and diagnosis of sepsis. As healthcare providers grapple with the complexities of managing infections caused by resistant organisms, the accuracy and effectiveness of existing diagnostic tests may be compromised. The growing healthcare burden associated with antibiotic resistance could lead to increased scrutiny of diagnostic solutions and drive demand for new methodologies that can accurately detect resistant strains. Consequently, the sepsis diagnostics market must adapt to these evolving challenges by investing in research and innovation to develop robust diagnostics that can address the threats posed by antibiotic resistance.

Competitor Outlook

• Abbott Laboratories
• Roche Diagnostics
• Becton, Dickinson and Company
• Siemens Healthineers
• Thermo Fisher Scientific
• bioMérieux SA
• Cepheid Inc.
• Hologic Inc.
• Beckman Coulter Inc.
• Randox Laboratories Ltd.
• Ortho Clinical Diagnostics
• GenMark Diagnostics Inc.
• Illumina Inc.
• Quidel Corporation
• Greiner Bio-One International GmbH

The competitive landscape of the sepsis diagnostics market is characterized by the presence of several key players, each striving to enhance their market position through innovation, strategic partnerships, and acquisitions. Major companies such as Abbott Laboratories and Roche Diagnostics are at the forefront of developing advanced diagnostic platforms that leverage cutting-edge technologies to improve sepsis detection and treatment outcomes. These companies invest heavily in research and development to introduce novel biomarkers and testing methodologies that cater to the evolving needs of healthcare providers. The competition in the market is further intensified by the entry of new players and the growing emphasis on point-of-care testing solutions, which provide rapid results and facilitate timely intervention.

In addition to technological advancements, companies are also focusing on enhancing their distribution networks and expanding their global reach to capitalize on emerging markets. For instance, Becton, Dickinson and Company and Siemens Healthineers have established strong distribution channels across various regions, enabling them to cater to healthcare providers’ diverse diagnostic needs effectively. Collaborations with hospitals and diagnostic laboratories to implement comprehensive sepsis management programs also play a significant role in strengthening their market presence. Furthermore, companies are increasingly engaging in strategic mergers and acquisitions to enhance their product portfolios and accelerate innovation, leading to a more competitive market landscape.

Some of the major players in the sepsis diagnostics market include bioMérieux SA and Thermo Fisher Scientific, both of which are renowned for their robust diagnostic solutions. bioMérieux SA has developed advanced microbiology systems and molecular diagnostics that play a crucial role in sepsis management, while Thermo Fisher Scientific is known for its innovative technologies that enable rapid detection of pathogens. These companies are continuously exploring new opportunities to enhance their offerings and address the growing demand for effective sepsis diagnostics. By focusing on customer-centric approaches and leveraging technological advancements, they aim to improve patient outcomes and maintain a competitive edge in the market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cepheid Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Illumina Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Roche Diagnostics
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Quidel Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Abbott Laboratories
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Beckman Coulter Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Siemens Healthineers
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 bioMérieux SA
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GenMark Diagnostics Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Randox Laboratories Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ortho Clinical Diagnostics
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Becton, Dickinson and Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Greiner Bio-One International GmbH
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Sepsis Diagnostics Market, By Test Type
    • 6.1.1 Blood Culture Test
    • 6.1.2 Biomarker Test
    • 6.1.3 Complete Blood Count
    • 6.1.4 Urine Analysis
    • 6.1.5 Other Tests
  • 6.2 Sepsis Diagnostics Market, By Technology
    • 6.2.1 Conventional Diagnostics and Automated Diagnostics
  • 6.3 Sepsis Diagnostics Market, By Application
    • 6.3.1 Hospitals
    • 6.3.2 Diagnostic Laboratories
    • 6.3.3 Research Laboratories
    • 6.3.4 Others
  • 6.4 Sepsis Diagnostics Market, By Product Type
    • 6.4.1 Blood Culture Systems
    • 6.4.2 Immunoassays
    • 6.4.3 Molecular Diagnostics
    • 6.4.4 Flow Cytometry
    • 6.4.5 Microbiology
    • 6.4.6 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Sepsis Diagnostics Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Sepsis Diagnostics market is categorized based on

By Product Type

• Blood Culture Systems
• Immunoassays
• Molecular Diagnostics
• Flow Cytometry
• Microbiology
• Others

By Application

• Hospitals
• Diagnostic Laboratories
• Research Laboratories
• Others

By Technology

• Conventional Diagnostics and Automated Diagnostics

By Test Type

• Blood Culture Test
• Biomarker Test
• Complete Blood Count
• Urine Analysis
• Other Tests

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Abbott Laboratories
• Roche Diagnostics
• Becton, Dickinson and Company
• Siemens Healthineers
• Thermo Fisher Scientific
• bioMérieux SA
• Cepheid Inc.
• Hologic Inc.
• Beckman Coulter Inc.
• Randox Laboratories Ltd.
• Ortho Clinical Diagnostics
• GenMark Diagnostics Inc.
• Illumina Inc.
• Quidel Corporation
• Greiner Bio-One International GmbH